LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated

Wei Zhou, Emory University
Jun Zhang, Emory University
Adam I Marcus, Emory University

Journal Title: Pathogenesis
Volume: Volume 1, Number 1
Publisher: Elsevier Ltd | 2014, Pages 64-74
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1016/j.gendis.2014.06.002
Permanent URL: https://pid.emory.edu/ark:/25593/pfv60

Final published version: http://dx.doi.org/10.1016/j.gendis.2014.06.002

Copyright information:
© 2014, Chongqing Medical University
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits making multiple copies, distribution, public display, and publicly performance, provided the original work is properly cited. This license requires credit be given to copyright holder and/or author, copyright and license notices be kept intact. This license prohibits exercising rights for commercial purposes.

Accessed January 26, 2019 1:23 PM EST
LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated

Wei Zhou*, Jun Zhang, Adam I. Marcus

Department of Hematology and Medical Oncology, The Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

Received 9 June 2014; accepted 13 June 2014
Available online 2 July 2014

Introduction

The current cancer treatment paradigm is to inhibit biological pathways that are hyperactive in cancer cells with pharmaceutical reagents. While these approaches have proven successful in the clinic, they share two common limitations. First, the targeted proteins or pathways are likely to play important physiological roles in some normal tissues, and their inhibition thus leads to toxic side effects. Second, cancer cells have defective DNA damage/repair checkpoint(s) which make them genetically unstable. Consequently, cancer cells are genetically heterogeneous, and each cell contains numerous pre-existing mutations that are not normally selected. Systemic therapy creates an environment for the selection of cancer cells with mutated target proteins that no longer interact with the drug. Therefore, side effects and secondary mutation-related
drug-resistance are two inevitable consequences of current cancer treatment approaches.

Tumor suppressor genes are not normally perceived as viable drug targets, and a common quote from pharmaceutical companies is “how can you target something that is not there?” It is important to note that even though Dr. Frank McCormick pioneered the concept of killing p53-null cells with the ONYX virus, the most successful clinical study of this virus was accompanied by evidence that ONYX-015 kills cancer cells through a mechanism that is not related to p53 inactivation. Recent studies have indicated that defects in the LKB1-AMPK signaling pathway make tumors vulnerable to varieties of stress, which can be exploited therapeutically.

Liver kinase 1 (LKB1 also known as STK11) is a tumor suppressor gene that is inactivated by bi-allelic mutation in non-small cell lung cancer (NSCLC), malignant melanoma and cervical cancer. Our knowledge of the biological roles of LKB1 has rapidly expanded over the past decade. Initial research focused on its roles in cell polarity, cell motility, protein translation and energy metabolism, and recent advances indicated that LKB1 is also involved in the regulation of other cellular process, such as DNA damage checkpoint, liposome function, and various signal transduction pathways. Hence, the inactivation of LKB1 in human tumors will lead to the de-regulation of multiple cellular processes, but it is still unclear which of them is related to tumorigenesis. From a treatment perspective, the lack of proper regulation should make cancer cells vulnerable to reagents that specifically inhibit these pathways. A therapeutic approach that can specifically eliminate LKB1-deficient cells will have at least two advantages. First, LKB1 is ubiquitously expressed in all tissue types, and therapeutic approaches against LKB1-null cells should have less toxic effects on normal tissues (i.e. fewer side effects). Second, LKB1 is frequently inactivated by bi-allelic genetic inactivation. Because the genetic codes for LKB1 are lost in these cancer cells, they are unlikely to be restored by genetic instability. Even if cancer cells find another way to restore LKB1 function, its tumor suppressor function should inhibit the growth of these cells. This review article will focus on the nature of these vulnerabilities and recent advances in the development of clinical re-agents that target these vulnerabilities in LKB1-null cancer cells (Table 1).

### LKB1 as a serine/threonine kinase

LKB1 protein has a central kinase domain, two N-terminal nuclear leading sequences, and a C-terminal regulatory motif. The protein also contains a CAAX motif at C-terminal end and can be farnesylated. The formation of an LKB1/Strad/MO25 complex is essential for LKB1’s kinase activity, and there are at least 13 known substrates of LKB1, which includes AMPKs, BRSKs, and MARKs. LKB1 is ubiquitously expressed in all tissues, so the mere presence of this protein does not inhibit cell proliferation. Existing data indicate that LKB1 kinase activity can be regulated either by post-translational modification of LKB1 itself or by the regulation of conformational configuration of its downstream targets. The upstream regulators of LKB1

### Table 1

<table>
<thead>
<tr>
<th>Class</th>
<th>Agents</th>
<th>Targets / Mechanisms</th>
<th>Stage of development</th>
<th>Comments</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMPK activators / stress inducers</td>
<td>Metformin</td>
<td>Inhibits mitochondria complex 1 and induces higher AMP/ATP ratio in LKB1 mutants</td>
<td>Phase 2</td>
<td>The phase 2 clinical trial NCT01266486 also included LKB1 status in the secondary outcome measures.</td>
<td>25-27</td>
</tr>
<tr>
<td></td>
<td>Phenformin</td>
<td>Targets mitochondria complex 1 and induces more severe energy stress in LKB1 mutants</td>
<td>Multiple phase 1 to 3 trials in malignancy and diabetes. Was withdrawn from market in 1978 due to rare but severe lactic acidosis in diabetic pts. Not currently in clinical trial</td>
<td></td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>AICAR</td>
<td>Induces apoptosis in LKB1-null MEF cells and ovarian cancer cells</td>
<td>Phase 1-2, but none for malignancies at this moment</td>
<td>Phase 1-2 trials now in multiple phase 1-3 clinical trials</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>Rapalogues (Everolimus, sirolimus, temsirolimus)</td>
<td>mTORC1</td>
<td>NCT01178151 is a phase 2 trial specifically for PJS</td>
<td></td>
<td>32, 34, 44</td>
</tr>
</tbody>
</table>
| | mTOR/HIF-1α | LOX inhibitors | | | (continued on next page)
<table>
<thead>
<tr>
<th>Class</th>
<th>Agents</th>
<th>Targets / Mechanisms that are \textit{LKB1} independent</th>
<th>Stage of development</th>
<th>Comments</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZD8055</td>
<td>ATP competitive inhibitor for both mTORC1 and mTORC2</td>
<td>Phase 1 but not specifically for LKB1 mutants</td>
<td>Preferentially reduced both LDH and PDH levels in a STK11^{+/−}/NIC breast cancer model</td>
<td></td>
<td>81</td>
</tr>
<tr>
<td>BAPN</td>
<td>LOX</td>
<td>Laboratory</td>
<td></td>
<td></td>
<td>82</td>
</tr>
<tr>
<td>PF573228</td>
<td>FAK inhibition in LKB1-null background</td>
<td>Laboratory</td>
<td></td>
<td></td>
<td>52, 53</td>
</tr>
<tr>
<td>Defactinib (PF-4554878, VS-6063)</td>
<td>FAK inhibition</td>
<td>Phase 1 &amp; 2 including a trial for KRAS mutant NSCLC, but not specific for LKB1</td>
<td>Needs more studies for LKB1 mutants</td>
<td></td>
<td>52</td>
</tr>
<tr>
<td>Dasatinib</td>
<td>Src inhibition</td>
<td>Phase 1 &amp; 2 for various malignancies. Not LKB1 specific.</td>
<td></td>
<td></td>
<td>52</td>
</tr>
<tr>
<td>AZD7762</td>
<td>CHK1 inhibition</td>
<td>Phase 1 (solid tumor). Not LKB1 specific.</td>
<td>Cardiac toxicity, neutropenia</td>
<td></td>
<td>54</td>
</tr>
<tr>
<td>CHIR124</td>
<td>CHK1 inhibition</td>
<td>Laboratory</td>
<td></td>
<td></td>
<td>54</td>
</tr>
<tr>
<td>DTYMK shRNA</td>
<td>DTYMK inhibition, reduce dTTP biosynthesis</td>
<td>Laboratory</td>
<td></td>
<td></td>
<td>54</td>
</tr>
<tr>
<td>Bafilomycin A1 (bafA)</td>
<td>Inhibits vacuolar ATPase</td>
<td>Laboratory</td>
<td></td>
<td></td>
<td>66</td>
</tr>
<tr>
<td>Saliphenylhalamide A (saliPhe)</td>
<td>Inhibits vacuolar ATPase</td>
<td>Laboratory</td>
<td></td>
<td></td>
<td>66</td>
</tr>
<tr>
<td>Dox-inducible YAP shRNA (iYAP shRNA)</td>
<td>Silences YAP</td>
<td>Laboratory</td>
<td></td>
<td></td>
<td>72, 73</td>
</tr>
<tr>
<td>Verteporfin</td>
<td>Disrupts the TEAD-YAP interaction</td>
<td>Laboratory</td>
<td></td>
<td></td>
<td>74</td>
</tr>
<tr>
<td>Super-TDU</td>
<td>Compete with YAP for the interaction with TEAD</td>
<td>Laboratory</td>
<td></td>
<td></td>
<td>75</td>
</tr>
</tbody>
</table>

Only LKB1 independent targets and mechanisms are listed. The information of clinical trials was obtained from www.clinicaltrials.gov. Although some of the listed agents have already been enrolled in clinical trials, only very few of them were specifically designed for LKB1 mutants. Also, some of the listed agents are still in silencing RNA formula, but due to their potentiality and good mechanistic studies, they are included here as well.

Abbreviations: \textit{AICAR}: 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside; \textit{DTYMK}: deoxythymidylate kinase; \textit{LOX}: lysyl oxidase; \textit{BAPN}: \textit{β}-aminopropionitrile; \textit{PJS}: Peutz–Jeghers Syndrome; \textit{LDH}: lactate dehydrogenase; \textit{PDH}: pyruvate dehydrogenase; \textit{NIC}: Neu/HER2-MMTV-Cre.
Mechanism of LKB1 inactivation in human tumors

Genetic inactivation of LKB1

LKB1 was first found to be associated with Peutz–Jeghers syndrome. This is an autosomal dominant disease that is characterized by gastrointestinal hamartomatous polyps, and elevated risk of various neoplasms. Many patients carry germline mutations that inactivate the kinase function of LKB1. This finding initiated intensive surveys for somatic LKB1 mutation analysis in human tumors, and LKB1 was subsequently found to be frequently mutated in non-small cell lung cancer (NSCLC), melanoma, and cervical cancers. The mutation frequency of LKB1 in NSCLC is still undetermined. Initial analysis in lung cancer cell lines indicated that LKB1 is inactivated in 30% of samples, but sub-sequence analysis in adenocarcinomas only revealed 5–15% point mutations. Part of this confusion is due to the fact that LKB1 is frequently inactivated by homozygous deletion which will not be detected by sequencing analysis alone. A combined analysis of homozygous deletion and LOH with somatic mutation indicated LKB1 is inactivated in 39% of NSCLC samples. Similarly, a combined sequencing and LKB1-large deletion analysis revealed 27% of Chinese lung adenocarcinomas contain LKB1 genetic alteration. The NextGen sequencing method should provide data on both somatic mutation and copy-number variations, and such analysis in the future should be able to provide a definitive number on LKB1 mutation frequencies in these tumor types.

LKB1 mutation was found to be rare in most other tumor types, which suggests that the deletion of LKB1 can only provide a growth advantage in certain tumor types. In the case of lung cancers, LKB1 mutation is limited to NSCLC. Adenocarcinoma of the lung contains the highest mutation frequency of LKB1, and LKB1 was also found to be mutated at lower frequencies in large cell and squamous cancer of the lung. Interestingly, a recent study in a mouse model shows that Lkb1-deficient lung adenocarcinoma (ADC) progressively transdifferentiates into squamous cell carcinoma (SCC) through pathologically mixed ADC–SCC intermediates. This finding immediately raised the following questions: (i) does human LKB1-mutant SCC also transdifferentiate from ADC, (ii) if so, does this transdifferentiation provides an advantage for tumor survival in the lung tissue microenvironment, and (iii) do human LKB1-mutant ADC and SCC have differential drug responses? Addressing the third question may have significant implications for the treatment approach to LKB1-mutated squamous lung cancer.

Epigenetic inactivation of LKB1

Although LKB1 is bona fide tumor suppressor gene, the lack of somatic LKB1 mutations in other major cancer types was puzzling. This led to the investigation of whether LKB1 can be inactivated in other cancer types through epigenetic modification. Initial analysis in 51 cancer cell lines indicated that three colorectal and one cervical carcinoma cell lines contain LKB1 promoter methylation. Similar analysis in 195 carcinomas of various tissue types revealed alterations in one colorectal carcinoma and three testicular carcinomas. The low frequency of LKB1 promoter methylation was also confirmed in colorectal cancer, hepatocellular carcinoma, and astrocytoma. The only exception reported is a recent study by a Korean group who found LKB1 promoter methylation in 13% of samples, and argued that LKB1 genetic and epigenetic alteration may vary depending on patient ethnicity. In general, LKB1 is not frequently inactivated in human cancers by epigenetic modification.

Biological inactivation of LKB1

Even though the epigenetic inactivation of LKB1 is a rare event in human cancer, a recent discovery is the discovery that the phosphorylation of AMPK by LKB1 is attenuated in melanoma cells with BRAF V600E activating mutation. Mechanistically, the presence of BRAF V600E mutation activates MEK/ERK signaling and its downstream target RSK. The phosphorylation of LKB1 at Ser325 and Ser428 by ERK2 and p90RSK was shown to be sufficient to inactivate LKB1 as an energy sensor through the disruption of LKB1’s interaction with its downstream effect molecule AMPK. Interestingly, LKB1’s interaction with Strad and MO25 was not affected in this specific scenario, and it is unknown whether LKB1 is still capable of interacting with its other downstream targets in the presence of BRAF V600E mutation. In any case, this example begs the question whether LKB1 can interact with other cellular components, and whether similar types of protein-protein interactions are also capable of inhibiting LKB1 kinase function. If these types of inhibitory proteins are present in other tumor types, targeted approaches against LKB1-deficient tumors may also be applicable in these tumors.

The unanticipated use of AMPK activators against LKB1-null tumor cells

Metformin, phenformin and AICAR are commonly used as AMPK activators even though their mechanisms of activation are different. Metformin and phenformin treatments inhibit mitochondria complex I, which can lead to the depletion of intracellular ATP and a rise in AMP. The binding of AMP to γ-regulator domain promotes the phosphorylation of AMPK at threonine 172 by upstream kinases, such as LKB1. This binding also protects the enzyme against dephosphorylation by phosphatases and causes allosteric activation of AMPK. LKB1 is also required in the process of AMPK activation because the farnesylation of LKB1 was recently found to be required for the activation of AMPK by phenformin.

Extensive experimental data indicates that the activation of AMPK by metformin or phenformin has anti-proliferative activity in many cancer types, but the underlying mechanisms are not completely understood. mTOR is one of the downstream targets that is inhibited by AMPK, which leads to inhibition of protein synthesis and cell proliferation. Another hypothesis is that tumor cells have defects in various aspects of lipid metabolism, and they are dependent on de-regulated lipid metabolism. The
activation of AMPK is capable of inhibiting lipid metabolism, thus suppressing cell proliferation. In summary, current data indicate that AMPK-dependent growth inhibition by metformin and phenformin in human cancers is LKB1-dependent.

An unexpected finding from studies of metformin and phenformin is that treatment of LKB1-null cells with these reagents leads to cell death. AMPK is not a mediator in this process because activated AMPK cannot be detected after such treatment. Therefore, LKB1-dependent AMPK activation is not the cause of this apoptosis. It should be noted that the inhibition of mitochondria complex I and the depletion of intracellular ATP by metformin and phenformin are LKB1-independent, so these reagents generate energetic stress regardless of LKB1 status. The mechanism underlying phenformin-induced cell death in LKB1-null cells was recently proposed. It was hypothesized that phenformin-induced ATP depletion is usually detected by the LKB1/AMPK metabolic checkpoint, whose activation re-balances the energy consumption in cancer cells to promote cell survival. However, LKB1-null cells cannot sense this defect, and the lack of proper energy consumption control eventually leads to cell death (Fig. 1). This hypothesis suggests that LKB1/AMPK plays a pro-survival role against phenformin-induced cell killing.

5-Aminoimidazole-4-carboxamide riboside (AICAR) is another commonly used AMPK activator. Inside a cell, AICAR is converted to AICAr monophosphate (ZMP) by adenosine kinase, and ZMP can act as an AMP analog to activate AMPK in an LKB1-dependent manner. Interestingly, the introduction of AICAR also induces caspase-3 cleavage in LKB1-null MEF cells and ovarian cancer cells, although the underlying mechanism(s) have not been explored. Even though AICAR-induced activation of AMPK has been shown to promote apoptosis in many cell lines, this type of apoptosis is usually dependent on the activation of AMPK. This is unlikely to be the mechanism in LKB1-null cells because genetic evidence shows that AMPK activation in response to treatment with AICAR is compromised in LKB1-/-MEFs, and can be restored following reconstitution of LKB1. Depending on the cell type, the introduction of AICAR may or may not lead to the depletion of ATP. Hence, it will be interesting to see in the future whether AICAR induces apoptosis in LKB1-null cells through a different mechanism, and whether LKB1/AMPK also provides a pro-survival role for cancer cells in this treatment setting.

Hyper-activated mTOR and ribosomal RNA synthesis in LKB1-null cells

mTOR is one of the earliest signaling pathways that was found to be negatively regulated by LKB1/AMPK signaling. Extensive experimental evidence indicates that mTOR-mediated protein translation is hyper-activated in cancer cells without LKB1, and various rapamycin analogs (rapalogs) have been developed to suppress the activity of mTORC1. This topic has been extensively reviewed elsewhere. Currently, these rapalogs (everolimus, sirolimus, temsirolimus) are in multiple phase 1-3 clinical trials, and NCT00178151 is a phase 2 trial that specifically evaluate the effects of everolimus in the treatment of advanced malignancies in patients with Peutz-Jeghers syndrome. Even though mTOR inhibitors have shown activities in some lung cancer patients, the underlying mechanism is still unknown. In a genetically engineered mouse model, invasive endometrial tumors derived from

---

**Figure 1** The effects of AMPK activators in LKB1-wild type and mutant cells. Metformin and phenformin inhibit mitochondria complex I, which results in the depletion of intracellular ATP and increases in AMP. The binding of AMP to the AMPK activates AMPK kinase activity and its metabolic regulation function. The lack of LKB1 prevents the activation of AMPK by AMP. As a result, metformin and phenformin induced energetic stress cannot be properly detected in LKB1-mutant cells, which eventually lead to cell death.
rDNA transcription or rRNA processing. In addition, hy-
with transcription factor SL1 and prevents the assembly
TIF-IA at Ser-635, which disrupts the interaction of TIF-IA
More recently, AMPK was found to directly phosphorylate
AMPK is involved in the regulation of rRNA transcription.
regulates mTOR, this is the first indirect evidence that
activation of rRNA transcription. Because AMPK negatively
indicates that AMPK is also involved in the regulation of pre-
rRNA synthesis through the inhibition of both mTOR and ribosome
synthesis. Currently, it is unknown whether the negative
regulation of pre-rRNA synthesis by AMPK is LKB1-
dependent. If this is the case, reagents that inhibit rRNA
transcription or rRNA maturation may also be used against
LKB1-null cancers.

**Sensitivity to Fak/Src inhibitors**

The role of LKB1 in regulating lung cancer invasion and metastasis is an emerging research field. Early studies in Drosophila indicated that LKB1 is involved in regulation of cell polarity, and the loss of epithelial polarity may be related to epithelial to mesenchymal transition (EMT). Direct evidence of LKB1’s involvement in cancer metastasis came from a study in a mutant Kras mouse model, in which the additional loss of Lkb1 accelerated primary and metastatic lung tumors. The negative correlation between LKB1 and FAK activation was also reported in human cancer cell lines where LKB1 was found to suppress FAK activity. These findings suggest that LKB1-null cancer cells may have hyper-activated SRC/FAK function, thus rendering them susceptible to SRC/FAK inhibition. Dasatinib is a Src inhibitor that is already in phase 1 and 2 clinical trials for various malignancies. Defactinib is a FAK inhibitor that is also in phase 1 and 2 clinical trials, one of which is a trial for Kras-mutant NSCLC patients. It will be interesting to see in the future whether these reagents can prevent the metastasis of LKB1-mutant tumors by targeting FAK or Src.

**LKB1 as a sensor for DNA damage**

A recent synthetic lethality screen revealed that the downregulation of DTYMK and Chk1 expression by RNAi preferentially induced cell killing in LKB1-null cells, and that LKB1-null cells accumulated more DNA damage than their isogenic LKB1-wild type counterparts. This finding suggested that LKB1 may play a role as a sensor for DNA damage, and that LKB1-mutant cells are defective in this DNA damage checkpoint. Consequently, these cells rely on Chk1’s function as the last defense against DNA damage, making Chk1 depletion a synthetic lethal combination with LKB1.

The puzzle here is how LKB1 acts as a sensor for DNA damage (Fig. 3). The most obvious question is whether nuclear LKB1 plays a role in this process. LKB1 has two nuclear leading sequences and LKB1 expression is present in the nucleus. Furthermore, decreased nuclear LKB1 levels correlate with HNSCC metastasis, suggesting that nuclear LKB1 is capable of suppressing HNSCC. A similar phenomenon was found in breast cancer, where the presence of nuclear LKB1 is associated with increased overall survival
Oxygen species (ROS). These data provided evidence that Kras/LKB1 mutant cell lines are addicted to some functions mediated by COPI. COPI is involved in various membrane-trafficking events, and is best known for its role in regulating mTOR through cytosolic ATM.

First, there is no direct evidence indicating that LKB1 can function as a kinase in the nucleus. The kinase function of LKB1 is mainly limited to the cytosol as the LKB1/STRAD/AMPK complex is mostly found in the cytosol. Even though STRADα is capable of passive diffusion into the nucleus, its main function appears to be to re-localize LKB1 into the cytosol. Second, even though AMPK was recently proposed as a sensor for genomic stress, the phosphorylation of AMPK after ionizing radiation (IR) in the nucleus is mostly mediated by ATM and ATR, and is observed in both LKB1-wild type and mutant cell lines. Therefore, ionization-mediated AMPK response in the nucleus appears to be LKB1-independent. These findings, however, do not necessarily rule out LKB1 as a sensor for genetic damage because the N-terminus of ATM does interact with LKB1, and ATM is capable of phosphorylating LKB1 at Thr-366. Interestingly, recent data indicated that ATM negatively regulates mTORC1 and induces autophagy via the LKB1/AMPK pathway in the cytoplasm, and cytoplasmic ATM is capable of activating LKB1/AMPK in response to reactive oxygen species (ROS). These data provided evidence that ATM and LKB1 may function as a sensor for oxidative stress in the cytosol. Because ROS is an important source of oxidative DNA damage, LKB1 may indirectly act as a sensor to control oxidative DNA damage. Consequently, reagents against DNA damage checkpoint proteins may be valuable for the treatment of LKB1-mutant cancer in the future.

Kras-LKB1 mutation-driven COPI addition

A recent study discovered that cancer cell lines with combined mutations in Kras and LKB1 are particularly sensitive to the depletion of coatomer complex I (COPI) subunits, such as ARCNI, COPB1 and COPA. These data suggest that Kras/LKB1 mutant cell lines are addicted to some functions mediated by COPI. COPI is involved in various membrane-trafficking events, and is best known for its role in coating vessels to be returned to the ER after they reach the cis or ER-Golgi intermediate compartment, a.k.a. retrograde transport. However, the authors presented evidence that Kras/LKB1 mutant cells are addicted to COPI’s role in lysosome acidification. Lysosomes are cellular vesicles containing many different acid hydrolases, which are capable of degrading various biomolecules, including proteins, carbohydrates, lipids, and nucleic acid. The acidification of lysosomes is an important step in their maturation process because many lysosomal enzyme precursors can only be properly cleaved into their mature form at acidic pH, and most lysosomal hydrolases are active only at acidic pH. In addition, the acidity also denatures proteins to make them easier to digest. Kras/LKB1-null cells were found to have more acidic lysosomes in their steady-state organelle accumulation. Therefore, these cells may be selectively dependent upon lysosomal maturation. Consistent with this, the vacuolar ATPase inhibitor bafilomycin A1 and saliphenylhalamide A were found to have selective toxicity against Kras/LKB1-mutant cell lines. Even though these reagents have only been tested in the laboratory setting, future development of clinical grade vacuolar ATPase inhibitors may have important implications in the treatment of Kras/LKB1 mutant lung cancers.

Hyper-activated YAP1 as a therapeutic target in LKB1-mutant cancers

The Hippo pathway is an ancient developmental pathway that regulates organ size and proliferation. It inhibits cell proliferation upon high cell density or stress, and can act as a tumor suppressor pathway in many tissues. One of the main downstream targets that is suppressed by the Hippo pathway is YAP1 (Yes-associated protein 1), a transcription co-activator that associates with the TEAD family of transcription factors to promote cell proliferation. In some cancers, such as melanoma, YAP1 is amplified to act as an oncogene. YAP1 has not been reported to be amplified in lung cancer, but elevated nuclear YAP1 expression has been observed and it negatively correlates with patient survival and LKB1 expression. In addition, RNAi knockdown of LKB1 significantly enhanced the transcription of YAP1-activated genes, and the over-expression of LKB1 inhibits YAP1-dependent transcription. Interestingly, YAP1 has also been shown functionally essential since the depletion of YAP1 reduced the growth of LKB1 mutant tumors, and its mutant form (YAP1 S217A) was able to significantly overcome all of LKB1’s tumor suppressive effects. LKB1 is a serine/threonine kinase. Even though LKB1 does not directly interact with YAP1, the over-expression of LKB1 correlates with an increase in the phosphorylation of YAP1 at Serine 127 and the degradation of YAP1 by the proteasome. RNAi analysis indicated that three LKB1 substrates (MARK, MST1, LATS1 and SCRIB) may form a Hippo regulator protein complex. Therefore, LKB1 is a suppressor of YAP1 function, and aberrant activation of YAP1 function may be another biological basis for the mutational inactivation of LKB1 in lung cancer. Because YAP1 is hyper-activated and is functionally essential in
LKB1-mutant cells, therapeutic strategies against YAP1 activation may be beneficial in the treatment of LKB1-mutant tumors (Fig. 4). Existing strategies include (i) the delivery of shRNA against YAP1, (ii) reagents that disrupt the YAP1/TEAD interaction (verteporfin), and (iii) reagents that compete with YAP for its interaction with STEAD (Super-TDU). These reagents are currently in pre-clinical development but they certainly represent an appealing strategy to eliminate LKB1-mutant cancers.

Vulnerability of LKB1-mutant cells to Hsp90 inhibitor, 17-AAG

The Genomics of Drug Sensitivity in Cancer (GDSC) recently published drug sensitivity data on 138 anticancer drugs in approximately 700 cancer cell lines, and LKB1-mutant cancer cell lines were found to be most sensitive to 17-AAG (http://www.cancerrxgene.org/translation/Gene/1367). 17-AAG (17-N-allylamino-17-demethoxygeldanamycin) is a derivative of geldanamycin, which was initially used to reveal a protein-protein interaction between LKB1 and Hsp90. Initially, Hsp90 and Cdc37 were found to bind specifically to the kinase domain of LKB1, and prevent ubiquitin-mediated LKB1 degradation by the proteasome. More recent data indicated that LKB1 in complex with Hsp90/Cdc37 has a longer half-life but lacks its autophosphorylation. Its kinase activity, however, can be transiently stimulated when it is released from Hsp90/Cdc37. A G163D point mutation in LKB1 was previously found to weaken the interaction between Hsp90/Cdc37, but it is unclear whether the weakened LKB1/Hsp90/Cdc37 interaction is responsible for the increased cancer cell sensitivity to 17-AAG. Furthermore, most LKB1-mutant cancer cell lines contain nonsense or frameshift mutations that usually abolish the production of LKB1 protein. Once again, LKB1 appears to play an unknown protective role in cancer cells against the toxicity of 17-AAG, and additional research is required to delineate the molecular basis for 17-AAG sensitivity of LKB1 mutant tumors.

On a side note, GDSC screen also included many therapeutic reagents currently used for the treatment of human cancers, such as paclitaxel, docetaxel, cisplatin, etc. None of these reagents have a growth inhibitory bias against LKB1-mutant cancer cell lines at statistical significant level. Hence, there is no direct evidence at this time for a selective or preferential reduction of LKB1-mutant cells by conventional cancer therapy, further supporting the needs in developing novel therapeutic reagents against LKB1-mutant tumors.

Conclusions

Therapeutic strategies against LKB1-mutant cancer are emerging, and their discovery can be classified into three categories. The first group is based on the biological function of LKB1 in regulating other signaling pathways. LKB1 was found to negatively regulate the activities of mTOR, FAK/Src, and YAP1, and LKB1-mutant cells may become dependent on the hyper-activation of these signaling pathways. Hence, inhibitory reagents against the function of these proteins should be useful for the treatment of LKB1-mutant cells. However, these reagents are not specifically designed against LKB1-mutant cells because these pathways may be aberrantly activated by mutations in other genes. The second group is based on unbiased synthetic lethality screening, and targeted inhibitions of proteins, such as Dtymk and Chk1, preferentially induces the killing of LKB1-null cells. The third group is associated with the function of LKB1 as a sensor for varieties of environment stresses, and cells with defective LKB1 appear unfit to detect such environmental insults. An interesting challenge in the future is to identify reagents, whose incorporation into the DNA, RNA or proteins will be detrimental for cell survival but can not be properly detected in LKB1-null cells. Such approach may lead to the development of unorthodox agents against LKB1-mutant cells which is not based on the inhibition of any proteins. It should be noted that these strategies may not be limited to cancer cells with LKB1 mutations because LKB1 can also be inactivated at the protein level by other proteins.

Conflict of interest

The authors declare no conflict of interest.
Acknowledgments

We would like to thank Dr. Anthea Hammond for editing this manuscript. WZ is an Anise McDaniel Brock Scholar, a Georgia Cancer Coalition Distinguished Cancer, and an American Cancer Society Research Scholar.

This work was supported in part by R01-CA140571, P01 CA116676, Anise McDaniel Brock Scholar fund to WZ, 1R01CA142858 to A.M., and P30CA138292 to Winship Cancer Institute.

References


